Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 324)
eröffnet am 31.08.08 11:55:05 von
neuester Beitrag 10.08.23 11:06:43 von
neuester Beitrag 10.08.23 11:06:43 von
Beiträge: 4.229
ID: 1.143.896
ID: 1.143.896
Aufrufe heute: 1
Gesamt: 285.565
Gesamt: 285.565
Aktive User: 0
ISIN: US84763A1088 · WKN: 164623 · Symbol: SPPI
1,0300
USD
0,00 %
0,0000 USD
Letzter Kurs 01.08.23 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
20.07.23 · Business Wire (engl.)  |
30.06.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5800 | +54,90 | |
| 24,500 | +22,50 | |
| 0,7000 | +16,67 | |
| 2,0400 | +16,50 | |
| 1,9380 | +16,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 160,90 | -14,14 | |
| 16,100 | -15,26 | |
| 4,0000 | -20,00 | |
| 0,7500 | -35,34 | |
| 2,1000 | -47,50 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 36.893.318 von Magnetfeldfredy am 01.04.09 06:13:11Die Eckdaten zu den Zahlen waren doch schon seit Anfang März bekannt.
Cash dürfte nun nur noch bei 50+x sein. Wobei x die Fusilev-Zahlungen aus Verkäufen darstellen. Denn zum weiterhin vorhandenen Cashburn kamen 24 Millionen für die Zevalin Aquisition (7,5 im Januar und 16,5 im März/April) drauf.
Hoffnungsträger für höhere Kurse sind nun
* Zevalin Zulassung Juli
* Fusilev Zulassung Oktober
* Asia Deal Apaziquone
und die Hoffnung, dass Fusilev sich dank noch etwas Shortage noch einigermassen gut verkauft.
Aktie notiert derzeit auf oder knapp unter Cash-Niveau. Erst wenn sichtbar und nachhaltig der Cashburn gestoppt werden kann, besteht Upside selbst in einem schrecklichen Markt wie diesem, dann aber großes Upside.
Es ist und bleibt pure Spekulation ob und wann dies der Fall sein wird.
Cash dürfte nun nur noch bei 50+x sein. Wobei x die Fusilev-Zahlungen aus Verkäufen darstellen. Denn zum weiterhin vorhandenen Cashburn kamen 24 Millionen für die Zevalin Aquisition (7,5 im Januar und 16,5 im März/April) drauf.
Hoffnungsträger für höhere Kurse sind nun
* Zevalin Zulassung Juli
* Fusilev Zulassung Oktober
* Asia Deal Apaziquone
und die Hoffnung, dass Fusilev sich dank noch etwas Shortage noch einigermassen gut verkauft.
Aktie notiert derzeit auf oder knapp unter Cash-Niveau. Erst wenn sichtbar und nachhaltig der Cashburn gestoppt werden kann, besteht Upside selbst in einem schrecklichen Markt wie diesem, dann aber großes Upside.
Es ist und bleibt pure Spekulation ob und wann dies der Fall sein wird.
Die MK liegt immer noch weit unter dem Barvermögen. Weder Fusilev noch Zevalin noch Eoquin sind irgendwo im aktuellen Kurs eingepreist.
Soviel zum Kurs der Spectrum Aktie
Soviel zum Kurs der Spectrum Aktie
Bei Spectrum haben sicher die Sektkorken geknallt.
Spectrum hat sich von einer forschenden Pommesbude (wie 90% aller gelisteten Biotechs) die Anlegergelder verbrennt zu einem erfolgreichen Medikamenten Hersteller entwickelt.
Wer an den Zahlen noch was negatives findet der hat das Konzept Biotech nicht verstanden.
Spectrum hat sich von einer forschenden Pommesbude (wie 90% aller gelisteten Biotechs) die Anlegergelder verbrennt zu einem erfolgreichen Medikamenten Hersteller entwickelt.
Wer an den Zahlen noch was negatives findet der hat das Konzept Biotech nicht verstanden.
Antwort auf Beitrag Nr.: 36.893.280 von Ville7 am 01.04.09 04:19:26Na, bist Du zufrieden mit den Zahlen, was werden die wohl für Kurse bringen?
Antwort auf Beitrag Nr.: 36.880.293 von Ville7 am 30.03.09 15:43:24Press Release Source: Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals Announces Fiscal Year 2008 Corporate Update and Pipeline Review
* ~ $78M in Cash & Equivalents as of December 31, 2008
* ~ $28.7M in 2008 Revenues, an Increase of 273%
* ~ 55% Reduction in Net Loss
* ~ 68% Reduction in Cash Use for Operations in 2008
* Tuesday March 31, 2009, 4:00 pm EDT
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008.
“We achieved a critical milestone in 2008 - the transition from a research and development to a commercial organization,” said Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Spectrum derives revenues from two FDA-approved, proprietary oncology drugs, has a late stage pipeline of novel products focused primarily on oncology and urology, and has a balanced business strategy involving judicious monetization of assets and fiscal discipline, executed by a highly experienced management team. As we develop our commercial infrastructure to capitalize on growth opportunities of our marketed products, we intend to achieve this in a staged manner and with fiscal prudence. We remain well capitalized in a financially challenging environment, and look forward to numerous important milestones in 2009.”
Major Value Drivers for 2009:
* ZEVALIN®
o July approval decision by FDA regarding use in 1st line consolidation treatment for non-Hodgkin’s Lymphoma;
o 100% Ownership of U.S. Sales and Marketing Rights;
o Establish reimbursement standards in concert with Center for Medical Services (CMS) for ZEVALIN by the 2nd quarter 2009.
* FUSILEV™
o October approval decision by FDA regarding use in advanced, metastatic colorectal cancer;
o Continued uptake of FUSILEV in community practices and institutions.
* Apaziquone (EOquin®)
o Complete enrollment in the two ongoing registrational Phase 3 clinical trials for non-muscle-invasive bladder cancer;
o Initiate trials in BCG-Refractory bladder cancer.
Fourth Quarter and Fiscal Year 2008 Results
Revenues for the fourth quarter ended December 31, 2008 were approximately $8.0 million, resulting in fiscal year revenues of $28.7 million, a 273% increase from the $7.7 million recorded in year 2007, primarily from the sale of the Company’s financial interests in sumatriptan injection to Par Pharmaceutical Companies, Inc., and the sales of FUSILEV™. The Company recorded a net loss of approximately $15.5 million, or ($0.49) per share for the year, a 55% decrease compared to $34.0 million, or ($1.17) in 2007. Research and development expenses were approximately $26.7 million, a 20% decrease compared to $33.3 million in 2007. General and administrative expenses were approximately $15.2 million, a 31% increase compared to $11.6 million in 2007, primarily due to higher selling expenses incurred for the launch FUSILEV.
During the year ended December 31, 2008, net cash used in operations was approximately $8.0 million, compared to net cash used in operations in fiscal 2007 of approximately $25.4 million. This 68% decrease of approximately $17.4 million is primarily due to the $20.7 million recorded as revenues from the sale of the financial interest in sumatriptan injection. As of December 31, 2008, the company had cash, cash equivalents, and marketable securities of approximately $78 million. There were approximately 32 million shares issued and outstanding as of March 27, 2009.
2008-2009 Achievements
In 2008 and early 2009 the Company accomplished the following key objectives:
* Generating more than $62 million in non-dilutive funding, while continuing our commitment to fiscal discipline in a challenging financial environment;
* Building a specialty sales force and marketing team with a proven track record in oncology;
* Receiving FDA-Approval and launching our first proprietary oncology drug, FUSILEV;
* Filing supplemental applications with the FDA for an additional formulation and indication for FUSILEV;
* Entering into a highly profitable development and commercialization alliance for apaziquone (EOquin®) with Allergan;
* Acquiring 100% rights to ZEVALIN in the U.S.;
* Strengthening our management team with the addition of key individuals to advance the Company's strategy.
The Company held a conference call on Thursday, February 26th, in which the Company provided top-line 2008 revenue and cash position. As a result, the company has elected to not host a conference call at this time. The company will host a conference call to discuss its 1st quarter 2009 financial update on or around May 15, 2009.
Spectrum Pharmaceuticals Announces Fiscal Year 2008 Corporate Update and Pipeline Review
* ~ $78M in Cash & Equivalents as of December 31, 2008
* ~ $28.7M in 2008 Revenues, an Increase of 273%
* ~ 55% Reduction in Net Loss
* ~ 68% Reduction in Cash Use for Operations in 2008
* Tuesday March 31, 2009, 4:00 pm EDT
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008.
“We achieved a critical milestone in 2008 - the transition from a research and development to a commercial organization,” said Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Spectrum derives revenues from two FDA-approved, proprietary oncology drugs, has a late stage pipeline of novel products focused primarily on oncology and urology, and has a balanced business strategy involving judicious monetization of assets and fiscal discipline, executed by a highly experienced management team. As we develop our commercial infrastructure to capitalize on growth opportunities of our marketed products, we intend to achieve this in a staged manner and with fiscal prudence. We remain well capitalized in a financially challenging environment, and look forward to numerous important milestones in 2009.”
Major Value Drivers for 2009:
* ZEVALIN®
o July approval decision by FDA regarding use in 1st line consolidation treatment for non-Hodgkin’s Lymphoma;
o 100% Ownership of U.S. Sales and Marketing Rights;
o Establish reimbursement standards in concert with Center for Medical Services (CMS) for ZEVALIN by the 2nd quarter 2009.
* FUSILEV™
o October approval decision by FDA regarding use in advanced, metastatic colorectal cancer;
o Continued uptake of FUSILEV in community practices and institutions.
* Apaziquone (EOquin®)
o Complete enrollment in the two ongoing registrational Phase 3 clinical trials for non-muscle-invasive bladder cancer;
o Initiate trials in BCG-Refractory bladder cancer.
Fourth Quarter and Fiscal Year 2008 Results
Revenues for the fourth quarter ended December 31, 2008 were approximately $8.0 million, resulting in fiscal year revenues of $28.7 million, a 273% increase from the $7.7 million recorded in year 2007, primarily from the sale of the Company’s financial interests in sumatriptan injection to Par Pharmaceutical Companies, Inc., and the sales of FUSILEV™. The Company recorded a net loss of approximately $15.5 million, or ($0.49) per share for the year, a 55% decrease compared to $34.0 million, or ($1.17) in 2007. Research and development expenses were approximately $26.7 million, a 20% decrease compared to $33.3 million in 2007. General and administrative expenses were approximately $15.2 million, a 31% increase compared to $11.6 million in 2007, primarily due to higher selling expenses incurred for the launch FUSILEV.
During the year ended December 31, 2008, net cash used in operations was approximately $8.0 million, compared to net cash used in operations in fiscal 2007 of approximately $25.4 million. This 68% decrease of approximately $17.4 million is primarily due to the $20.7 million recorded as revenues from the sale of the financial interest in sumatriptan injection. As of December 31, 2008, the company had cash, cash equivalents, and marketable securities of approximately $78 million. There were approximately 32 million shares issued and outstanding as of March 27, 2009.
2008-2009 Achievements
In 2008 and early 2009 the Company accomplished the following key objectives:
* Generating more than $62 million in non-dilutive funding, while continuing our commitment to fiscal discipline in a challenging financial environment;
* Building a specialty sales force and marketing team with a proven track record in oncology;
* Receiving FDA-Approval and launching our first proprietary oncology drug, FUSILEV;
* Filing supplemental applications with the FDA for an additional formulation and indication for FUSILEV;
* Entering into a highly profitable development and commercialization alliance for apaziquone (EOquin®) with Allergan;
* Acquiring 100% rights to ZEVALIN in the U.S.;
* Strengthening our management team with the addition of key individuals to advance the Company's strategy.
The Company held a conference call on Thursday, February 26th, in which the Company provided top-line 2008 revenue and cash position. As a result, the company has elected to not host a conference call at this time. The company will host a conference call to discuss its 1st quarter 2009 financial update on or around May 15, 2009.
Trading Spotlight
Antwort auf Beitrag Nr.: 36.879.965 von Magnetfeldfredy am 30.03.09 15:07:05Das weiss nur Spectrum. Schau dir die letzten 6 Jahre an, da kamen sie immer im März. Es ist unüblich, dass wir jetzt schon so lange warten müssen.
Antwort auf Beitrag Nr.: 36.873.312 von Ville7 am 29.03.09 08:10:06Wann genau kommen die Zahlen? Danke vorab!
Antwort auf Beitrag Nr.: 36.878.317 von VaJo am 30.03.09 11:47:32Bei Reuters verschiebt sich die Skala immer weiter in Richtung kaufen
Wie kommst'n darauf? Current, 1Month ago, 2 Month ago und 3 Month ago unverändert bei 2.0. Da hat sich null verändert.
Wie kommst'n darauf? Current, 1Month ago, 2 Month ago und 3 Month ago unverändert bei 2.0. Da hat sich null verändert.
http://www.reuters.com/finance/stocks/recommendations?symbol…
Bei Reuters verschiebt sich die Skala immer weiter in Richtung kaufen
Bei Reuters verschiebt sich die Skala immer weiter in Richtung kaufen
Die Q4 und Jahreszahlen sind schon zwei Wochen über die übliche Zeit hinaus. Ich vermute, dass es Verzögerungen wegen der Zevalin Aquisition gibt. Meine Hoffnung: Zahlen in der kommenden Woche. Wobei die wichtigsten Eckdaten schon bekannt sind: 78 Mio Cash und 10 Mio Fusilev Sales bis Jahresende von denen ein Großteil in 2008 verbucht werden sollte.
Durchsuchen
